Dyne Therapeutics DYN

$ 24.0 -1.23%

Quarterly report 2024-Q3
added 11-12-2024

Dyne Therapeutics Balance Sheet 2011-2024 | DYN

Annual Balance Sheet Dyne Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-94.2 M	-142 M	-168 M	-301 M	-14.6 M	-8.12 M	8.07 B	7.2 B	6.78 B	5.24 B	1.15 B	1.07 B	192 M
Long Term Debt	22.7 M	25.9 M	28.7 M	-	-	-	8.33 B	8.78 B	7.21 B	7.08 B	1.98 B	1.39 B	584 M
Long Term Debt Current	4.72 M	4.61 M	3.89 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	42 K	12.4 M	8.48 B	8.95 B	7.42 B	7.31 B	2.26 B	1.74 B	734 M
Total Current Liabilities	51.1 M	28.1 M	28.7 M	11 M	-	-	-	-	-	-	-	-	-
Total Liabilities	73.8 M	54 M	57.5 M	11 M	2.4 M	13.1 M	9.87 B	11 B	8.62 B	8.21 B	3.08 B	2.03 B	3.02 B
Deferred Revenue	-	-	-	-	-	-	7 M	5 M	29 M	20 M	100 M	95 M	5 M
Retained Earnings	-633 M	-397 M	-228 M	-79.2 M	-19.7 M	-4.89 M	-1.85 B	-1.93 B	-686 M	-736 M	-463 M	-107 M	-4.84 B
Total Assets	165 M	306 M	426 M	353 M	16.4 M	8.27 M	11.8 B	13.1 B	11.5 B	11.2 B	5.29 B	4.54 B	4.13 B
Cash and Cash Equivalents	122 M	172 M	201 M	301 M	-	-	-	-	-	-	-	-	-
Book Value	91.3 M	252 M	368 M	342 M	14 M	-4.88 M	1.9 B	2.04 B	2.92 B	3.02 B	2.21 B	2.5 B	1.11 B
Total Shareholders Equity	91.3 M	252 M	368 M	342 M	14 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Dyne Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	20 M	20.9 M	21.9 M	22.7 M	23.5 M	24.3 M	25.1 M	25.9 M	26.6 M	-	28.1 M	28.7 M	29.4 M	-	-	-	9.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	63.3 M	50.7 M	44.2 M	73.8 M	53.2 M	44.5 M	46.7 M	54 M	49.9 M	-	51.3 M	57.5 M	52.8 M	14.6 M	13.4 M	11 M	11 M	11 M	11 M	2.4 M	2.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-860 M	-763 M	-698 M	-633 M	-566 M	-506 M	-441 M	-397 M	-358 M	-	-264 M	-228 M	-177 M	-134 M	-104 M	-79.2 M	-79.2 M	-79.2 M	-79.2 M	-19.7 M	-19.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	769 M	826 M	522 M	165 M	205 M	251 M	289 M	306 M	300 M	-	388 M	426 M	467 M	467 M	492 M	353 M	353 M	353 M	353 M	16.4 M	16.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	532 M	608 M	272 M	122 M	130 M	168 M	181 M	172 M	145 M	-	148 M	201 M	229 M	258 M	311 M	301 M	301 M	301 M	301 M	14.6 M	14.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	706 M	775 M	478 M	91.3 M	152 M	207 M	242 M	252 M	250 M	-	336 M	368 M	414 M	453 M	478 M	342 M	342 M	342 M	342 M	14 M	14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	706 M	775 M	478 M	91.3 M	152 M	207 M	242 M	252 M	250 M	287 M	336 M	368 M	414 M	453 M	478 M	342 M	342 M	342 M	342 M	14 M	14 M	-8.46 M	-6.96 M	-4.88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency